CIK 0000811641 · Non-accelerated filer<br>Smaller reporting company
IMMUCELL CORP /DE/
Sign in to watch- Ticker
- ICCC
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010382980
- Phone
- 2078782770
- Business address
- 56 EVERGREEN DR, PORTLAND, ME, 04103
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-18 | te Boekhorst Paul Francis Olivier President and CEO | Purchase | +8,000 | $9.50 | $76K | 17,785 |
| 2026-04-15 | Turner Kathy V Director | Grant or award · Non Qualified Stock Options (Right to buy) | +17,899 | 17,899 | ||
| 2026-04-15 | Tomsche David Scott Director | Grant or award · Non Qualified Stock Options (Right to buy) | +11,933 | 11,933 | ||
| 2026-04-15 | Basse Gloria F Director | Grant or award · Non Qualified Stock Options (Right to buy) | +11,933 | 11,933 | ||
| 2026-04-15 | Wainman Paul R Director | Grant or award · Non Qualified Stock Options (Right to buy) | +11,933 | 11,933 | ||
| 2026-03-20 | BRIGHAM MICHAEL F Director | Option exercise | +25,000 | $5.84 | $146K | 229,752 |
| 2026-03-20 | BRIGHAM MICHAEL F Director | Shares withheld for taxes | −24,052 | $6.07 | $146K | 205,700 |
| 2026-03-20 | BRIGHAM MICHAEL F Director | Option exercise · Stock Options (right to buy) | −25,000 | 0 | ||
| 2026-01-27 | te Boekhorst Paul Francis Olivier President and CEO | Grant or award · Stock Options (right to buy) | +109,500 | 109,500 | ||
| 2026-01-27 | Fiori Timothy C Chief Financial Officer | Grant or award · Stock Options (right to buy) | +120,000 | 120,000 | ||
| 2026-01-27 | Brockmann Bobbi Jo VP of Sales and Marketing | Grant or award · Stock Options (right to buy) | +100,000 | 100,000 | ||
| 2026-01-27 | te Boekhorst Paul Francis Olivier President and CEO | Grant or award · Stock Options (right to buy) | +110,000 | 110,000 | ||
| 2025-12-04 | te Boekhorst Paul Francis Olivier President and CEO | Purchase | +2,432 | $5.50 | $13K | 9,738 |
| 2025-12-03 | te Boekhorst Paul Francis Olivier President and CEO | Purchase | +3,598 | $5.05 | $18K | 7,306 |
| 2025-12-03 | te Boekhorst Paul Francis Olivier President and CEO | Purchase | +2,556 | $5.00 | $13K | 6,264 |
| 2025-12-03 | te Boekhorst Paul Francis Olivier President and CEO | Purchase | +3,521 | $5.04 | $18K | 9,785 |
| 2025-12-02 | te Boekhorst Paul Francis Olivier President and CEO | Purchase | +3,708 | $4.87 | $18K | 3,708 |
| 2025-11-25 | Tomsche David Scott Director | Purchase | +1,633 | $4.76 | $8K | 52,720 |
| 2025-11-25 | Tomsche David Scott Director | Purchase | +1,633 | $4.77 | $8K | 4,740 |
| 2025-11-07 | te Boekhorst Paul Francis Olivier President and CEO | Grant or award · Stock Options (right to buy) | +74,277 | $6.10 | $453K | 150,260 |
Page 1 of 11 · 209 trades